Question special

No differences were observed across the AR101 group and the placebo group with respect to clinical characteristics (including past or present asthma) as discussed in Table 1. I am curious as to whether this was an expected finding, and if there was adequate power to assess efficacy and adverse event rates across different patient cohorts? I imagine a post-marketing study would help to delineate mediators of efficacy as well.